Condition: Interstitial Lung Disease Due to Systemic Disease · Scleroderma · Sponsor: Scleroderma Research Foundation, Inc.
The goal of this clinical trial is to test efficacy of different investigational products (IPs) compared with placebo on the change from baseline to the end of the treatment period at Week 52 in lung capacity in participants with Interstitial Lung Disease Secondary to Systemic Sclerosis.
This description comes directly from the study's public registry record.
Gabrielle Khedr · 415.834.9444 · inquiries@conquestssc.org
Kevin O'Shea · 415.834.9444 · inquiries@conquestssc.org
Always discuss trial participation with your own doctor first.
| University of Alabama - Division of Pulmonary and Critical Care Medicine | Birmingham, Alabama, United States | Recruiting |
| Keck School of Medicine at USC Medical Center | Los Angeles, California, United States | Recruiting |
| Cedars-Sinai Medical Center | Los Angeles, California, United States | Recruiting |
| University of California, Los Angeles (UCLA) Ronald Reagan Medical Center | Los Angeles, California, United States | Withdrawn |
| Stanford University Medical Center | Palo Alto, California, United States | Recruiting |
| Yale University School of Medicine - Epilepsy | New Haven, Connecticut, United States | Withdrawn |
| Georgetown University Medical Center - Department of Rheumatology | Washington D.C., District of Columbia, United States | Recruiting |
| Emory University School of Medicine | Atlanta, Georgia, United States | Recruiting |
| Northwestern University | Chicago, Illinois, United States | Recruiting |
| The University of Chicago Medical Center (UCMC) | Chicago, Illinois, United States | Recruiting |
| University of Kansas School of Medicine | Kansas City, Kansas, United States | Recruiting |
| Johns Hopkins University School of Medicine | Baltimore, Maryland, United States | Recruiting |
+ 22 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06195072